Which paid more, BIOY or FINY?

From May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting price in cash and FINY paid 8.9%, so BIOY paid more. Cash paid is not the same as money made: the price change matters too.

Which returned more once distributions are counted, BIOY or FINY?

With every distribution reinvested, BIOY returned +5.4% and FINY +9.8% from May 5, 2026 to Nov 4, 2026.

Which is cheaper, BIOY or FINY?

BIOY and FINY both charge 1.18% a year, so neither is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Income ETFs

BIOY vs FINY: Dividend Yield & Total Return

Share on X Download as PDF

Over the window both share to Nov 4, 2026, BIOY paid 26.1% of its price in cash against FINY’s 8.9%, though FINY returned more with it reinvested.

askIQ about this page

askIQ about BIOY and FINY

Net assets on Nov 3, 2026: $1.5m for GraniteShares YieldBOOST Biotech ETF and $747,148 for GraniteShares YieldBOOST Financials ETF.

BIOY on its own →FINY on its own →

At a glance

26.1%

BIOY cash paid, since launch, May 5, 2026

8.9%

FINY cash paid, since launch, May 5, 2026

+5.4%

BIOY total return, since launch, May 5, 2026

+9.8%

FINY total return, since launch, May 5, 2026

BIOY · since launch to Nov 4, 2026 13.6 pts behind XBI

BIOY

+5.4%

XBI

+19.0%

13.6 pts behind XBI

BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.

XBI

+19.0%

BIOY

+5.4%

26.1% as cash

13.6 pts behind XBI

Total return, distributions reinvested

13.6 pts behind XBI

BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.

XBI

+19.0%

BIOY

+5.4%

13.6 pts behind XBI

26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.

Data to Nov 4, 2026.

FINY · since launch to Nov 4, 2026 5.8 pts behind XLF

FINY

+9.8%

XLF

+15.6%

5.8 pts behind XLF

FINY since launch: paid 8.9%, price +0.5%, total +9.8%, XLF +15.6%, −5.8 pts. Data to Nov 4, 2026.

XLF

+15.6%

FINY

+9.8%

8.9% of it arrived as cash

5.8 pts behind XLF

Total return, distributions reinvested

5.8 pts behind XLF

FINY since launch: paid 8.9%, price +0.5%, total +9.8%, XLF +15.6%, −5.8 pts. Data to Nov 4, 2026.

XLF

+15.6%

FINY

+9.8%

5.8 pts behind XLF

8.9% of it arrived as cash. Both charts share one scale, with zero at the line. FINY since launch: paid 8.9%, price +0.5%, total +9.8%, XLF +15.6%, −5.8 pts. Data to Nov 4, 2026.

Data to Nov 4, 2026.

Pair scorecard

Both cost 1.18% a year.

Points (pts) are percentage points.

BIOY vs FINY: Dividend Yield & Total Return
Measure	BIOY	FINY
Paid and earned
Measure	BIOY	FINY
Price change, since May 5, 2026	fell 21.9%	rose 0.5%
Return of capital, issuer estimate	96% of the Sep 22, 2026 payment	96% of the Jul 7, 2026 payment
Against its benchmark
Measure	BIOY	FINY
Benchmark	Biotech, measured through XBI	Financials sector, measured through XLF
Cost and size
Measure	BIOY	FINY
Expense ratio	1.18%	1.18%
Net assets, as of Nov 3, 2026	$1.5m	$747,148
Holdings
Measure	BIOY	FINY
Holdings in common	0%

Method

What they share

By the books each fund has filed, BIOY and FINY hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026.

50%

0 half 100%

half

0% in common

Check overlap with more funds →

Side by side

BIOY GraniteShares YieldBOOST Biotech ETF · Synthetic covered call on XBI, paying weekly FINY GraniteShares YieldBOOST Financials ETF · Synthetic covered call on XLF, paying weekly

Issuer GraniteShares GraniteShares

Strategy synthetic covered call synthetic covered call

Benchmark Biotech (XBI) Financials sector (XLF)

Pays weekly weekly

Payout rate, annualized 60.7% 11.2%

Expense ratio 1.18% 1.18%

Cash paid, 1 year 26.1% (since launch, May 5, 2026) 8.9% (since launch, May 5, 2026)

Price change, 1 year −21.9% (since launch, May 5, 2026) +0.5% (since launch, May 5, 2026)

Total return, 1 year +5.4% (since launch, May 5, 2026) +9.8% (since launch, May 5, 2026)

Benchmark return, 1 year +19.0% (since launch, May 5, 2026) +15.6% (since launch, May 5, 2026)

Ahead or behind −13.6 pts (since launch, May 5, 2026) −5.8 pts (since launch, May 5, 2026)

Return of capital, latest estimate 96% 96%

Age 183 days 183 days

Net assets, as of Nov 3, 2026 $1.5m $747,148

As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.

Window by window

Window by window: BIOY vs FINY: Dividend Yield & Total Return
	Total return		Cash paid		Against the benchmark
Window	BIOY	FINY	BIOY	FINY	BIOY	FINY
3 months	+6.9%	+1.3%	14.5%	2.9%	+2.9 pts	−1.2 pts
6 months	+4.4%	+9.6%	25.9%	8.9%	−11.3 pts	−5.4 pts
Since launchBIOY May 2026 · FINY May 2026	+5.4%	+9.8%	26.1%	8.9%	−13.7 pts	−5.7 pts

Open this comparison in the app →

Alert

About each fund

BIOY

Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.

FINY

Over the period from its first trade on May 5, 2026 to Nov 4, 2026, FINY paid 8.9% of its starting value in cash distributions while its price rose 0.5%. With every distribution reinvested, the fund returned +9.8%. Financials sector (XLF) returned +15.6% over the same days, so a holder was behind by 5.8 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 11.2%, paid weekly. GraniteShares estimates that 96% of the distribution paid Jul 7, 2026 was a return of capital (its 19a-1 notice).

Questions people ask

Which paid more, BIOY or FINY?: From May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting price in cash and FINY paid 8.9%, so BIOY paid more. Cash paid is not the same as money made: the price change matters too.
Which returned more once distributions are counted, BIOY or FINY?: With every distribution reinvested, BIOY returned +5.4% and FINY +9.8% from May 5, 2026 to Nov 4, 2026.
Which is cheaper, BIOY or FINY?: BIOY and FINY both charge 1.18% a year, so neither is cheaper. Fees come from each fund's prospectus.

Other comparisons

BIOY vs XLFI BIOY vs TECY BIOY vs XLCI BIOY vs YRAM FINY vs XLCI FINY vs WEPN FINY vs TECY FINY vs YRAM

Where to next

Biotech (XBI) →Financials sector (XLF) →All income ETFs ranked by the Distribution Coverage Score →How the scores are computed →BIOY on its own →FINY on its own →BIOY dividend history →FINY dividend history →Method →Standards and sources →

Sources and dates

BIOY and FINY filings on SEC EDGAR ↗

BIOY and FINY prospectus with the expense ratio (SEC) ↗

BIOY 19a-1 distribution notice ↗

GraniteShares page for BIOY ↗

FINY 19a-1 distribution notice ↗

GraniteShares page for FINY ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, BIOY against FINY, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-finy

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.